Russell Investments Group, Ltd. Apellis Pharmaceuticals, Inc. Transaction History

Russell Investments Group, Ltd.

$66.8 Billion
Q3 2024

A detailed history of Russell Investments Group, Ltd. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 3,231 shares of APLS stock, worth $105,589. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,231

Previous 4,482 27.91%

Holding current value

$105,589

Previous $171,000 45.61%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$28.84 - $41.15 $36,078 - $51,478	-1,251 Reduced 27.91%	3,231 $93,000
Q2 2024 Aug 08, 2024	BUY	$38.07 - $59.71 $34,110 - $53,500	896 Added 24.99%	4,482 $171,000
Q1 2024 May 08, 2024	BUY	$55.39 - $72.47 $184,448 - $241,325	3,330 Added 1300.78%	3,586 $210,000
Q4 2023 Feb 05, 2024	SELL	$37.14 - $64.82 $1.31 Million - $2.28 Million	-35,215 Reduced 99.28%	256 $15,000
Q3 2023 Nov 13, 2023	SELL	$23.65 - $89.22 $2.41 Million - $9.11 Million	-102,056 Reduced 74.21%	35,471 $1.35 Million
Q2 2023 Aug 10, 2023	SELL	$76.68 - $93.31 $51,605 - $62,797	-673 Reduced 0.49%	137,527 $12.5 Million
Q1 2023 May 09, 2023	BUY	$46.59 - $66.96 $3.09 Million - $4.44 Million	66,325 Added 92.28%	138,200 $9.12 Million
Q4 2022 Feb 08, 2023	SELL	$43.24 - $61.04 $703,298 - $992,815	-16,265 Reduced 18.45%	71,875 $3.72 Million
Q3 2022 Nov 04, 2022	BUY	$44.76 - $69.66 $1.79 Million - $2.79 Million	40,082 Added 83.4%	88,140 $6.02 Million
Q2 2022 Jul 29, 2022	BUY	$35.07 - $59.21 $10,836 - $18,295	309 Added 0.65%	48,058 $2.17 Million
Q1 2022 May 05, 2022	SELL	$35.46 - $54.12 $2.13 Million - $3.26 Million	-60,202 Reduced 55.77%	47,749 $2.42 Million
Q4 2021 Jan 21, 2022	SELL	$30.74 - $49.16 $506,687 - $810,304	-16,483 Reduced 13.25%	107,951 $5.1 Million
Q3 2021 Nov 08, 2021	BUY	$31.4 - $69.84 $1.51 Million - $3.36 Million	48,126 Added 63.07%	124,434 $4.1 Million
Q2 2021 Aug 04, 2021	SELL	$40.9 - $64.9 $763,316 - $1.21 Million	-18,663 Reduced 19.65%	76,308 $4.82 Million
Q1 2021 May 10, 2021	BUY	$40.8 - $57.39 $2.2 Million - $3.1 Million	53,952 Added 131.53%	94,971 $4.07 Million
Q4 2020 Feb 08, 2021	SELL	$30.79 - $57.2 $1.58 Million - $2.94 Million	-51,342 Reduced 55.59%	41,019 $2.35 Million
Q3 2020 Nov 09, 2020	BUY	$25.89 - $33.65 $1.5 Million - $1.95 Million	57,940 Added 168.33%	92,361 $2.78 Million
Q2 2020 Aug 05, 2020	BUY	$24.8 - $38.49 $309,801 - $480,817	12,492 Added 56.97%	34,421 $1.12 Million
Q1 2020 May 06, 2020	BUY	$17.91 - $44.33 $392,748 - $972,112	21,929 New	21,929 $587,000
Q1 2019 May 13, 2019	SELL	$12.81 - $19.82 $736,293 - $1.14 Million	-57,478 Closed	0 $0
Q4 2018 Feb 11, 2019	SELL	$11.47 - $18.71 $33,675 - $54,932	-2,936 Reduced 4.86%	57,478 $758,000
Q3 2018 Oct 26, 2018	BUY	$16.57 - $21.03 $171,665 - $217,870	10,360 Added 20.7%	60,414 $1.07 Million
Q1 2018 May 11, 2018	BUY	$14.01 - $26.02 $701,256 - $1.3 Million	50,054 New	50,054 $1.11 Million

Others Institutions Holding APLS

# of Institutions

308

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.59B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account

Russell Investments Group, Ltd. Apellis Pharmaceuticals, Inc. Transaction History